Journals / Turkish Thoracic Journal / 2020 / Cilt: 21 - Sayı: 2

Dilatation Reserve of Pulmonary Arteries at Stages of the Chronic Obstructive Pulmonary Disease Model

Pages
105–109
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This led to a decrease in the inflence of vasodilators on pulmonary artery vascular tone and could facilitatethe development of pulmonary hypertension, which is typical of COPD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVES: To assess the state of pulmonary vascular mediator systems during the stepwise formation of the chronic obstructive pulmonary disease (COPD) model.MATERIALS AND METHODS: The COPD model was induced in rats by nitrogen dioxide (NO2) inhalation for 60 days.
📊
Key Findings & Data:At different stagesof COPD (15, 30, and 60 days), the effect of reagents-vasodilators (β-adrenoceptor agonist isoproterenol, nitric oxide donor nitrosorbide,acetylcholine, activator of C-fiers capsaicin, corticosteroid beclometasone) on the isolated pulmonary arteries (diameter <0.5 mm)was studied.
💡
Conclusion & Impact:This led to a decrease in the inflence of vasodilators on pulmonary artery vascular tone and could facilitatethe development of pulmonary hypertension, which is typical of COPD.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

OBJECTIVES: To assess the state of pulmonary vascular mediator systems during the stepwise formation of the chronic obstructive pulmonary disease (COPD) model.MATERIALS AND METHODS: The COPD model was induced in rats by nitrogen dioxide (NO2) inhalation for 60 days. At different stagesof COPD (15, 30, and 60 days), the effect of reagents-vasodilators (β-adrenoceptor agonist isoproterenol, nitric oxide donor nitrosorbide,acetylcholine, activator of C-fiers capsaicin, corticosteroid beclometasone) on the isolated pulmonary arteries (diameter <0.5 mm)was studied. Vascular reactivity was assessed by determining isometric contraction (tension in milligrams) of arterial rings by using anelectromechanical transducer.RESULTS: All vasodilators dose-dependently decreased the vascular tone of pulmonary arteries isolated from intact rats. After 15 days ofNO2 exposure, dilatation effect of low doses of vasodilators did not differ from that of intact specimens. The functional state of the adrenergic system deteriorated faster than that of the nonadrenergic noncholinergic system as reflcted by the weakening of the isoproterenolrelaxation effect. On prolonged NO2 exposure, pulmonary arteries responded to the impact of all vasodilators with smaller relaxation.Dose dependence of the dilatation reaction disappeared for isoproterenol, capsaicin, beclometasone, and was less expressed for nitrosorbide and acetylcholine after 60 days of exposure.CONCLUSION: In the course of COPD model generation, the functioning of almost all neurotransmitter systems of pulmonary arterywall was negatively affected. This led to a decrease in the inflence of vasodilators on pulmonary artery vascular tone and could facilitatethe development of pulmonary hypertension, which is typical of COPD.

🔖

Cite This Article

KUZUBOVA, N. A., LEBEDEVA, E. S., TİTOVA, O. N., PREOBRAZHENSKAYA, T. N. (2020). Dilatation Reserve of Pulmonary Arteries at Stages of the Chronic Obstructive Pulmonary Disease Model. Turkish Thoracic Journal, Cilt: 21 - Sayı: 2, 105–109. https://ajindex.com/articles/417945

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Burger CD. Pulmonary hypertension in COPD: a review and consideration of the role of arterial vasodilators. COPD 2009
  2. [CrossRef] 2. Chhabra SK. Pulmonary hypertension associated with chronic obstructive pulmonary disease. Ind J Chest Dis Allied Sci 2010
  3. Nakazawa H, Hori M, Ozaki H, et al. Mechanisms underlying the impairment of endothelium-dependent relaxation in the pulmonary artery of monocrotaline-induced pulmonary hypertensive rats. Br J Pharmacol 1999
  4. [CrossRef] 4. Yang Q, Underwood MJ, Hsin MK, et al. Dysfunction of pulmonary vascular endothelium in chronic obstructive pulmonary disease: basic considerations for future drug development. Curr Drug Metab 2008
  5. [CrossRef] 5. Zakynthinos E, Daniil Z, Papanikolaou G, et al. Pulmonary hypertension in COPD: pathophysiology and therapeutic targets. Curr Drug Targets 2011
  6. [CrossRef] 6. Malerba M, Romanelli G. Early cardiovascular involvement in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 2009
  7. [CrossRef] 7. van Zutphen LFM, Baumans V, Beynen AC, editors. Principles of Laboratory Animal Science, rev. ed. Amsterdam: Elsevier
  8. Lebedeva ES, Kuzubova NA, Danilov LN, et al. Experimental modelling of chronic obstructive pulmonary disease. Bull Exper Biol Med 2012
  9. [CrossRef] 9. Blattner R, Classen HG, Dehnert H, et al. Experiments on isolated smooth muscle preparations. Freiburg: Hugo Sachs Elektronik KG
  10. English edition prepared by Barnden IM, Colson R. 1980:185. 10. Timmermans PB, Chiu AT, Thoolen MJ. Calcium handling in vasoconstriction to stimulation of alpha 1- and alpha 2-adrenoreceptors. Can J Physiol Pharmacol 1987
  11. [CrossRef] 11. Hamada H, Damron DS, Hong SJ, et al. Phenylephrine-induced Ca2+ oscillations in canine pulmonary artery smooth muscle cells. Circul Res 1997
  12. [CrossRef] 12. Taddei S, Virdis A, Ghiadoni L, et al. Role of endothelin in the control of peripheral vascular tone in human hypertension. Heart Fail Rev 2001
  13. [CrossRef] 13. Fedin AN, Kuzubova NA, Danilov LN, et al. Dysfunction of airway nervous structures in rats inhaled with nitrogen dioxide. Russ J Physiol 2007
  14. Jernigan NL, Broughton BRS, Walker BR, et al. Impaired NOdependent inhibition of store- and receptor-operated calcium entry in pulmonary vascular smooth muscle after chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2006
  15. L517-25. [CrossRef] 15. Mendes ES, Horvath G, C